Importantly, a previous study (5) reported that the prognosis was poorer in GC patients with higher PD-L1 expression than those patients with lower PD-L1 expression, although immune checkpoint blockade (ICB) drugs such as nivolumab have been reported to be effective in patients with unresectable, advanced, or recurrent G/GEJ cancer, which was validated by preclinical findings (6–8). This evidence concerns the gene CD274 and gastric cancer.